Sickle Cell Disease

Crizanlizumab reduces sickle cell-related pain

Crizanlizumab reduces sickle cell-related pain

By

Treatment with high-dose crizanlizumab resulted in an annual rate of sickle cell-related pain crises that was 45.3% lower compared with placebo.

Sign Up for Free e-newsletters